D. Norbeck

发表

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

D. Ho, M. Markowitz, J. Leonard, 1996, Nature Medicine.

Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy.

A. Molla, S. Vasavanonda, D. Norbeck, 1998, Journal of medicinal chemistry.

Evaluation of substituted benzamides as P2 ligands for symmetry-based inhibitors of HIV protease

S. Vasavanonda, D. Norbeck, D. Kempf, 1995 .

Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.

D. Norbeck, D. Kempf, J. Erickson, 1990, Science.

Influence of Stereochemistry on Activity and Binding Modes for C2 Symmetry-Based Diol Inhibitors of HIV-1 Protease

Dale J. Kempf, John W. Erickson, Eric T. Baldwin, 1994 .

Stereocontrolled synthesis of C2-symmetric and pseudo-C2-symmetric diamino alcohols and diols for use in HIV protease inhibitors

D. Norbeck, D. Kempf, R. Henry, 1992 .

Cyclobut-A and cyclobut-G, carbocyclic oxetanocin analogs that inhibit the replication of human immunodeficiency virus in T cells and monocytes and macrophages in vitro

D. Norbeck, H. Mitsuya, S. Broder, 1990, Antimicrobial Agents and Chemotherapy.

Evaluation of furofuran as a P2 ligand for symmetry-based HIV protease inhibitors

S. Vasavanonda, D. Norbeck, D. Kempf, 1996 .

Novel a- and b-Amino Acid Inhibitors of Influenza Virus Neuraminidase

V. Stoll, V. Giranda, D. Norbeck, 2001 .

Novel α- and β-Amino Acid Inhibitors of Influenza Virus Neuraminidase

V. Stoll, V. Giranda, D. Norbeck, 2001, Antimicrobial Agents and Chemotherapy.

(±)-Dioxolane-T ((±)-1-[(2β,4β)-2-(hydroxymethyl)-4-dioxolanyl]thymine): a new 2',3'-dideoxynucleoside prototype with in vitro activity against HIV

D. Norbeck, H. Mitsuya, S. Broder, 1989 .

Efficiency of phosphorylation of the cyclobut-G (A-69992) enantiomers by HSV-1 thymidine kinase does not correlate with their anti-herpesvirus activity.

S. Fesik, D. Norbeck, J. Erickson, 1990, Biochemical pharmacology.

Synthesis of azacyclic 2-deoxy-KDO

D. Norbeck, J. B. Kramer, 1987 .

Synthesis of an isosteric phosphonate analog of cytidine 5'-monophospho-3-deoxy-D-manno-2-octulosonic acid

D. Norbeck, P. Lartey, J. B. Kramer, 1987 .

Novel lopinavir analogues incorporating non-Aromatic P-1 side chains--synthesis and structure--activity relationships.

S. Vasavanonda, D. Norbeck, D. Kempf, 2002, Bioorganic & medicinal chemistry letters.

The convergent synthesis of polyether ionophore antibiotics: the synthesis of the monensin spiroketal

D. Norbeck, D. Haebich, R. Ireland, 1985 .

The convergent synthesis of polyether ionophore antibiotics: an approach to the synthesis of the monensin tetrahydropyran-bis(tetrahydrofuran) via the ester enolate Claisen rearrangement and reductive decarboxylation

D. Norbeck, G. Mandel, N. Mandel, 1985 .

Synthesis of (-)-oxetanocin

D. Norbeck, J. B. Kramer, 1988 .

Application of the Swern oxidation to the manipulation of highly reactive carbonyl compounds

D. Norbeck, R. Ireland, 1985 .

Chapter 16. Recent Advances in Anti-retroviral Chemotherapy for AIDS

D. Norbeck, 1990 .

Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS.

D. Norbeck, J. Erickson, H. Sham, 1990, Journal of medicinal chemistry.

Convergent synthesis of polyether ionophore antibiotics: the synthesis of the monensin bis(tetrahydrofuran) via the Claisen rearrangement of an ester enolate with a .beta.-leaving group

D. Norbeck, R. Ireland, 1985 .

Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir).

A. Molla, S. Vasavanonda, D. Norbeck, 2001, Bioorganic & medicinal chemistry letters.

Efficacy of A-73209, a potent orally active agent against VZV and HSV infections.

D. Norbeck, M. Mitten, E. Kern, 1994, Antiviral research.

Synthesis and activities of the phosphonate isostere of the monophosphate of (±)cyclobut-G

D. Norbeck, H. Sham, J. Plattner, 1992 .

Synthesis of (±)-cycloprop-G, the cyclopropyl analogue of the broad spectrum antiviral agent cyclobut-G

D. Norbeck, H. Sham, J. Plattner, 1992 .

ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease

Dale J. Kempf, John M. Leonard, Jacob J. Plattner, 1998, Antimicrobial Agents and Chemotherapy.

In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 Variants with Increased Resistance to ABT-378, a Novel Protease Inhibitor

Dale J. Kempf, William E. Kohlbrenner, John M. Leonard, 1998, Journal of Virology.

Inhibition of 3C protease from human rhinovirus strain 1B by peptidyl bromomethylketonehydrazides.

D. Norbeck, H. Sham, J. McCall, 1999, Archives of biochemistry and biophysics.

Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease

S. Vasavanonda, D. Norbeck, D. Kempf, 1991, Antimicrobial Agents and Chemotherapy.

Effects of purine nucleoside analogues with a cyclobutane ring and erythromycin A oxime derivatives on duck hepatitis B virus replication in vivo and in cell culture and HIV‐1 in cell culture

P. Hung, D. Norbeck, P. Marion, 1991, Journal of medical virology.

A C2 symmetry-based HIV protease inhibitor, A77003, irreversibly inhibits infectivity of HIV-1 in vitro.

D. Norbeck, D. Kempf, J. Erickson, 1994, AIDS research and human retroviruses.

Lack of stereospecificity in the binding of the P2 amino acid of ritonavir to HIV protease

A. D. Rodrigues, S. Muchmore, A. Molla, 1997 .

Facile synthesis of potent HIV-1 protease inhibitors containing a novel pseudo-symmetric dipeptide isostere

D. Norbeck, D. Kempf, H. Sham, 1993 .

A novel prodrug of an impermeant inhibitor of 3-deoxy-D-manno-2-octulosonate cytidylyltransferase has antibacterial activity.

D. Norbeck, P. Lartey, W. Rosenbrook, 1989, Journal of Medicinal Chemistry.

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir

A. D. Rodrigues, J. Leonard, A. Hsu, 1997, Antimicrobial agents and chemotherapy.

Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus.

J. Leonard, A. Molla, S. Vasavanonda, 1998, Virology.

Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease.

L. Everitt, A. Kaplan, D. Norbeck, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Structure-based, C2 symmetric inhibitors of HIV protease.

S. Vasavanonda, D. Norbeck, D. Kempf, 1990, Journal of medicinal chemistry.

Potent HIV-1 protease inhibitors with antiviral activities in vitro.

S. Vasavanonda, D. Norbeck, D. Kempf, 1991, Biochemical and biophysical research communications.

In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations

J. Weinstein, D. Norbeck, D. Kempf, 1992, Antimicrobial Agents and Chemotherapy.

InVitro Inhibition ofHumanImmunodeficiency Virus(HIV)Type1 Replication byC2Symmetry-Based HIVProtease Inhibitors asSingle Agents orinCombinations

D. Norbeck, J. Erickson, T. Shirasaka, 1992 .

Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor

D Norbeck, D. Ho, D. Norbeck, 1994, Journal of virology.

Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease

J. Leonard, J. Bilello, D. Norbeck, 1996, Antimicrobial agents and chemotherapy.

Synthesis and activity of N-acyl azacyclic urea HIV-1 protease inhibitors with high potency against multiple drug resistant viral strains.

V. Stoll, S. Vasavanonda, D. Norbeck, 2005, Bioorganic & medicinal chemistry letters.

Human immunodeficiency virus type 1 virions composed of unprocessed Gag and Gag-Pol precursors are capable of reverse transcribing viral genomic RNA

A. Kaplan, D. Norbeck, D. Kempf, 1994, Antimicrobial Agents and Chemotherapy.

Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles

A. Kaplan, D. Norbeck, D. Kempf, 1993, Journal of virology.

to a C2-symmetric protease inhibitor. virus type 1 variants with increased resistance Characterization of human immunodeficiency

D. Norbeck, D. Kempf, J. Erickson, 2016 .

Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor

D. Ho, T. Bhat, M. Markowitz, 1995, Journal of virology.

Genotypic Changes in Human Immunodeficiency Virus Type 1 Associated with Loss of Suppression of Plasma Viral RNA Levels in Subjects Treated with Ritonavir (Norvir) Monotherapy

John M. Leonard, P. Scott Eastman, Mickey Urdea, 1998, Journal of Virology.

Novel lopinavir analogues incorporating heterocyclic replacements of six-member cyclic urea--synthesis and structure-activity relationships.

S. Vasavanonda, D. Norbeck, H. Sham, 2004, Bioorganic & medicinal chemistry letters.

Synthesis and SAR studies of potent HIV protease inhibitors containing novel dimethylphenoxyl acetates as P2 ligands.

S. Vasavanonda, D. Norbeck, D. Kempf, 2003, Bioorganic & medicinal chemistry letters.

Synthesis and structure-activity relationships of a novel series of HIV-1 protease inhibitors encompassing ABT-378 (Lopinavir).

S. Vasavanonda, D. Norbeck, D. Kempf, 2002, Bioorganic & medicinal chemistry letters.

A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease.

A. Molla, S. Vasavanonda, N. Lyons, 1996, Journal of medicinal chemistry.

Synthesis of (2S,5S,4R)-2,5-diamino-3,3-difluoro-1,6-diphenylhydroxyhexane: the core unit of a potent HIV proteinase inhibitor

D. Norbeck, D. Kempf, J. Erickson, 1991 .

X-ray crystallographic structure of ABT-378 (lopinavir) bound to HIV-1 protease.

V. Stoll, R. Simmer, D. Norbeck, 2002, Bioorganic & medicinal chemistry.

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.

S. Vasavanonda, D. Norbeck, D. Kempf, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Chapter 15. HIV Protease Inhibitors

D. Norbeck, D. Kempf, 1991 .

Novel azacyclic ureas that are potent inhibitors of HIV-1 protease.

A. Molla, S. Vasavanonda, D. Norbeck, 1996, Biochemical and Biophysical Research Communications - BBRC.

Pseudo‐symmetrical difluoroketones

S. Vasavanonda, D. Norbeck, D. Kempf, 1993, FEBS letters.